Helus Pharma (STU:R7E) Research & Development: €74.42 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:R7E Helus Pharma Inc STU:R7E
38 GF Score
Price €6.39
! 2 Warning Signs
View Full Analysis

What is Helus Pharma Research & Development?

Helus Pharma STU:R7E +2.73% 38 Research & Development is €74.42 Mil as of Mar. 2026. GuruFocus rates STU:R7E with a GF Score™ of 38/100. The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Helus Pharma's Research & Development for the three months ended in Mar. 2026 was €24.99 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was €74.42 Mil.

Helus Pharma  (STU:R7E) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Helus Pharma Research & Development Related Terms

Helus Pharma Research & Development Historical Data

* Premium members only.

The historical data trend for Helus Pharma's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Helus Pharma Research & Development Chart

Helus Pharma Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Research & Development
Get a 7-Day Free Trial 12.79 17.60 22.04 36.27 74.90

Helus Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.23 13.00 16.06 20.37 24.99
STU:R7E
38GF Score
Helus Pharma Inc STU:R7E
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Helus Pharma Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €74.42 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €74.42 Mil mean?
Helus Pharma (STU:R7E) has a Research & Development of €74.42 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Helus Pharma and its competitors.
Is Helus Pharma's Research & Development too high?
Helus Pharma's current Research & Development is €74.42 Mil. Overall, Helus Pharma has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Helus Pharma's Research & Development compare to VRTX and REGN?
Helus Pharma's Research & Development of €74.42 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Helus Pharma and its competitors. Helus Pharma's current Research & Development is €74.42 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Helus Pharma stock overvalued right now?
Helus Pharma (STU:R7E) has a current Research & Development of €74.42 Mil. The current Research & Development is €74.42 Mil. Helus Pharma's overall GF Score™ is 38/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Helus Pharma (STU:R7E), the current Research & Development is €74.42 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Helus Pharma Business Description

Other Exchanges HELP:USAHELP:Canada
Address 100 King Street West, Suite 5600, Toronto, ON, CAN, M5X 1C9
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.
38GF Score

Get the complete analysis for STU:R7E

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.39
Price